Daiichi and Lilly to Test Prasugrel Against Clopidogrel
Posted on: Monday, 5 November 2007, 12:00 CST
Daiichi Sankyo and Eli Lilly & Co. have announced plans to begin a new large Phase III clinical trial of prasugrel in the second quarter of 2008. The 10,000 patient study will compare the investigational oral antiplatelet agent with clopidogrel for the management of acute coronary syndrome.
Daiichi Sankyo Company, and Eli Lilly and Company, which are co-developing prasugrel, will conduct the study in conjunction with the Duke Clinical Research Institute (DCRI). Lead study investigator is Magnus Ohman, professor of cardiology at Duke University School of Medicine.
The study, TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes), will include approximately 10,000 patients at more than 800 hospitals in 35 countries. TRILOGY ACS will evaluate the safety and efficacy of prasugrel against clopidogrel in reducing the risk of cardiovascular death, heart attack or stroke in acute coronary syndrome (ACS) patients who are to be medically managed without planned revascularization (a procedure to reopen blocked arteries).
John Alexander, global head of R&D, Daiichi Sankyo Company, said: "The announcement of this study demonstrates our continued confidence in the clinical research surrounding prasugrel."
Source: Datamonitor
Related Articles
- Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients
- VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
- BioStorage Technologies Serves As Repository for Landmark Study of Coronary Artery Disease
- VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
- The Medicines Company's Angiox(R) Receives European Authorization for Expanded Use in Patients With Acute Coronary Syndromes (ACS)
- VIA Pharmaceuticals Announces Funding for Pharmacogenomic Sub-Study on VIA-2291 ACS Trial
- MERLIN TIMI-36 Study Accepted As Late Breaking Clinical Trial at American College of Cardiology Annual Scientific Session
- Cytori Therapeutics Reports Safety and Efficacy of Its Celution System(TM) in a Preclinical Study of Coronary Artery Disease; Outlines Design of Planned Chronic Ischemia Clinical Study in Europe
- Study Examines Continued Economic Burden of Acute Coronary Syndrome Despite Standard Medical Interventions
- Nuvelo BEGINS Phase 2 'Proof of Concept' Trial Evaluating rNAPc2 in Patients Being Treated for Acute Coronary Syndromes (ACS)
 |
 |
User Comments (0)
RSS Feeds